ImmunoVaccine Technologies (IVT) will obtain C$3 million from the Atlantic Canada Opportunities Agency (ACOA) to develop new potent immune enhancement systems. The funding was received under the Atlantic Innovation Fund. The work will be a part of a C$6 million project.
“This funding will enable us, over the next three years, to create novel vaccines for the treatment of cancer and infectious diseases,” comments Brian Lowe, vp. IVT also says that the financing will further its research collaborations and commercialization opportunities with pharmaceutical companies worldwide.
IVT developed a vaccine-enhancement technology called the VacciMax®. It comprises a mixture of liposomes and adjuvants. The platform is able to stimulate an earlier, more powerful, long-lasting immune response that could provide a new way to treat a wide range of diseases, according to the firm.